CoronaVac

This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.

coronavac

Whole inactivated SARS-CoV-2 vaccine (CZ02 strain, Vero-cell propagated, BPL-inactivated, alum-adjuvanted) by Sinovac Biotech. 2-dose IM schedule. WHO EUL June 2021. Pivotal role in COVAX and LMICs; 65.9% VE hospitalization, 86.3% VE death in Chile real-world (Jara 2021 NEJM).

Entry Metadata

Field	Value
ID	coronavac
Name	CoronaVac
Status	active
Last reviewed	2026-06-04
Platform	04 — Inactivated
Delivery system	aluminum hydroxide adjuvanted inactivated virus
Adjuvants	aluminum hydroxide
Route	intramuscular
Dose schedule	2 doses, 0 and 14 days (or 0 and 28 days)
Manufacturer	Sinovac Biotech (China)
Cold chain	2–8°C (refrigerator stable)

Cross-Atlas Connections

immunizes-againstSars Cov 2 elicitsImmune System elicitsImmunoglobulin G elicitsB Cell elicitsT Helper Cell preventsCovid 19 Disease

Sources

Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. JAMA. 2021;326(1):35-45.
Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213-222.
Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385(10):875-884.